期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Preparation and identification of monoclonal antibodies against the adenovirus vector
1
作者 Chunyan Zhang Jinsong Gong Yan Chen Fanghe Li 《The Chinese-German Journal of Clinical Oncology》 CAS 2007年第4期411-414,共4页
Objective: To prepare and identity monoclonal antibodies (McAbs) against the capsid proteins of adenovirus vector. Methods: BALB/c mice were immunized with a mixture of the purified adenovirus vector (Adv) and A... Objective: To prepare and identity monoclonal antibodies (McAbs) against the capsid proteins of adenovirus vector. Methods: BALB/c mice were immunized with a mixture of the purified adenovirus vector (Adv) and AI(OH)3. McAbs were produced using cell fusion technique in a conventional way. The sensitivity and specificity of monoclonal antibodies was identified by indirect enzyme linked immunosorbent assay (ELISA), immunocytochemical staining and Western blotting. Results: Six strains of hybridoma cells (A4H11, A8C7, F1H5, G1D2, G4E3 and H2G8) that can stably secrete the IgG1 McAb against Adv were obtained. After 3 months subculture and low concentration of serum adapting culture, six strains retained their stability to secrete McAb. The ascites titers were between 1:10^6 and 1:10^8. Western blot analysis demonstrated that all the McAbs reacted with one protein (about 114 kDa) which is present in wild type 3 adenovirus (wtAd3), wild type 5 adenovirus (wtAd5), wild type 7 adenovirus (wtAd7) and adenovirus vector. Conclusion: Successfully prepared six strains of hybridoma cell secreted monoclonal antibodies against the hexon proteins of adenovirus vector, and provided the substantial foundation of preclinical research of adenovirus vectors. 展开更多
关键词 gene therapy ADENOVIRUS adenovirus vector monoclonal antibodies
下载PDF
Ad-ERα-36-Fc-GFP的制备及鉴定 被引量:1
2
作者 谢雨琼 李春春 +3 位作者 李晓烨 陈丽红 严毛晓 曹江 《生物工程学报》 CAS CSCD 北大核心 2022年第3期1086-1095,共10页
ERα-36是雌激素受体α新亚型,促进肿瘤细胞增殖、侵袭及耐药,可作为治疗靶点,但目前仅有小分子靶向药物研发。利用重组腺病毒携带诱饵受体,可进行靶向ERα-36的基因治疗探索。首先通过基因工程技术,构建可表达由Igκ信号肽引导分泌的... ERα-36是雌激素受体α新亚型,促进肿瘤细胞增殖、侵袭及耐药,可作为治疗靶点,但目前仅有小分子靶向药物研发。利用重组腺病毒携带诱饵受体,可进行靶向ERα-36的基因治疗探索。首先通过基因工程技术,构建可表达由Igκ信号肽引导分泌的重组融合蛋白ERα-36-Fc的穿梭质粒pDC316-Igκ-ERα-36-Fc-GFP;利用AdMax;腺病毒包装系统进行Ad-ERα-36-Fc-GFP腺病毒的包装、鉴定及扩增;感染三阴性乳腺癌细胞MDA-MB-231并进行表达及功能验证。结果表明成功制备Ad-ERα-36-Fc-GFP重组腺病毒,可高效感染三阴性乳腺癌细胞MDA-MB-231,表达并分泌ERα-36-Fc重组蛋白,显著抑制EGFR/ERK信号通路。Ad-ERα-36-Fc-GFP腺病毒的制备为进一步开展靶向ERα-36的肿瘤基因治疗研究奠定基础。 展开更多
关键词 Ad-ERα-36-Fc-GFP 腺病毒制备 诱饵受体 基因治疗
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部